Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.

NCT04008706 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04008706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04008706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
September 17, 2019
Completion date
November 4, 2025
Enrollment
552 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia